Antiproteasic agents in the prevention of post-ERCP pancreatitis: Rationale for use and clinical results

Journal of the Pancreas

Volumn 4, Issue 1, 2003, Pages 75-82

  Cavallini, Giorgio ^a   Frulloni, Luca ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b Policlinico GB Rossi   (Italy)

Author keywords

Acute disease; Chemicals and drugs category; Cytokines; Gabexate; Pancreatitis; Primary prevention; Protease inhibitors; Serine proteinase inhibitors

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA INTERFERON; CAMOSTAT; CATHEPSIN B; ELASTASE; ENTEROPEPTIDASE; GABEXATE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; LYSOSOME ENZYME; NAFAMSTAT; PANCREAS ENZYME; PHOSPHOLIPASE A; PLACEBO; PLASMIN; PROTEINASE INHIBITOR; TAUROCHOLIC ACID; TRYPSIN; TRYPSINOGEN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PANCREATITIS; ARTICLE; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG MECHANISM; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SURGERY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; NONHUMAN; PANCREAS DUCT; PANCREAS ISLET CELL; PATHOGENESIS; ANIMAL; ENZYMOLOGY; METHODOLOGY; PANCREATITIS; REVIEW; TREATMENT OUTCOME;

ANIMALS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; HUMANS; PANCREATITIS; PROTEASE INHIBITORS; TREATMENT OUTCOME;

EID: 0037268177     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Hofbauer B, Saluja AK, Lerch MM, Bhagat L, Bhatia M, Lee HS, et al. Intra-acinar cell activation of trypsinogen during cerulein-induced pancreatitis in rats. Am J Physiol 1998; 275:G352-62. [AN 98365352]
2. Saluja AK, Steer ML. Pathophysiology of pancreatitis: role of cytokines and other mediators of inflammation. Digestion 1999; 60 (Suppl 1):1260-1264.
3. Hartwig W, Jimenez RE, Werner J, Lewandrowski KB, Warshaw AL, Fernandez-Del Castillo C. Interstitial trypsinogen release and its relevance to the transformation of mild into necrotizing pancreatitis in rats. Gastroenterology 1999; 117:717-25. [AN 99395008]
4. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med 1994; 330:1198-210. [AN 94187814]
5. Chiari H. Übewr selbstverdauung des menschlichen pancreas. Z Heilkunde 1896; 17:69-95.
6. Steer ML. Frank Brooks Memorial Lecture: the early intraacinar events which occurs during acute pancreatitis. Pancreas 1998: 17:31-7. [AN 98330091]
7. Watanabe O, Baccino FM, Steer ML, Meldolesi J. Supramaximal cerulein stimulation and ultrastructure of rat changes during development of experimental pancreatitis. Am J Physiol 1984; 246:G457-67. [AN 84200532]
8. Koike H, Steer ML, Meldolesi J. Pancreatic effect of ethionine: blockade of exocytosis and appearance of crinophagy and autophagy precede cellular necrosis. Am J Physiol 1982; 242:G297-307. [AN 82157690]
9. Lerch MM, Saluja AK, Runzi M, Dawra R, Saluja M, Steer ML. Pancreatic duct obstruction triggers acute necrotizing pancreatitis in opossum. Gastroenterology 1993; 104:853-61. [AN 93178844]
10. Saluja A, Saluja M, Villa A, Leli U, Rutledge P, Meldolesi J, Steer M. Pancreatic duct obstruction in rabbits causes digestive zymogen and lysosomal enzyme colocalization. J Clin Invest 1989; 84:1260-6. [AN 90009320]
11. Greenbaum LM, Hirshkowitz A, Stoichet I. The activation of trypsinogen by cathepsin B. J Biol Chem 1959; 234:2885-90.
12. Figarella C, Miszczuk-Jamska B, Barrett A. Possibile lysosomal activation of pancreatic zymogens. Activation of both human trypsinogens by cathepsin B and spontaneous acid. Activation of human trypsinogen-1. Biol Chem Hoppe-Seyler 1988; 369:293-8. [AN 89076524]
13. Saluja AK, Donovan EA, Yamanaka K, Yamaguchi Y, Hofbauer B, Steer ML. Cerulein-induced in vitro activation of trypsinogen in rat pancreatic acini is mediated by cathepsin B. Gastroenterology 1997; 113:304-10. [AN 97350915]
14. Van Acker GJ, Saluja AK, Bhagat L, Singh VP, Song AM, Steer ML. Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatic severity. Am J Physiol 2002; 283:G794-800. [AN 22168742]
15. Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger M, Reinheckel T, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 2000; 106:773-81. [AN 20453314]
16. Hartwig W, Werner J, Jimenez RE, Z'graggen K, Weimann J, Lewandrowski KB, et al. Trypsin and activation of circulating trypsinogen contribute to pancreatic-associated lung injury. Am J Physiol 1999; 277:G1008-16. [AN 20035074]
17. Buchler M, Malfertheiner P, Schadlich H, Nevalainen J, Friess H, Beger HG. Role of phospholipase A2 in human acute pancreatitis. Gastroenterology 1989; 97:1521-6. [AN 90060590]
18. Lungarella G, Gardi C, De Santi MM, Luzi P. Pulmonary vascular injury in pancreatitis: evidence for a major role played by pancreatic elastase. Exp Mol Pathos 1985; 42:44-59. [AN 85101929]
19. Kusske AM, Rongione AJ, Reber HA. Cytokines and acute pancreatitis. Gastroenterology 1996; 110:639-42. [AN 96156071]
20. Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg 2002; 9:401-10. [AN 22371300]
21. Brady M, Christmas S, Sutton R, Neoptolemos J, Slavin J. Cytokines and acute pancreatitis. Ballieres Best Pract Clin Gastroenterol 1999; 13:265-89. [AN 20483523]
22. Moore FA, Moore EE. Evolving concept in the pathogenesis of post injury multiple organ failure. Surg Clin North Am 1995; 75:257-77. [AN 95207905]
23. Niederau C, Liddle RA, Ferrell LD, Grendell JH. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. J Clin Invest 1986; 78:1056-63. [AN 87009029]
24. Ohshio G, Saluja AK, Leli U, Sengupta A, Steer ML. Esterase inhibitors prevent lysosomal enzyme redistribution in two non invasive models of experimental pancreatitis. Gastroenterology 1989; 96:853-9. [AN 89121405]
25. Niederau C, Crass RA, Silver G, Ferrell LD, Grendell JH. Therapeutic regimens in acute experimental hemorragic pancreatitis. Gastroenterology 1988; 95:1648-57. [AN 89031826]
26. Leonhardt U, Seidensticker F, Stockmann F, Creutzfeldt W. Effect of camostate administration for two weeks on experimental pancreatitis in mice and rats. Pancreas 1993; 8:98-102. [AN 93126306]
27. Wisner JR Jr, Ozawa S, Renner IG. The effect of nafamostat mesilate (FUT-105) on cerulein induced acute pancreatitis in the rat. Int J Pancreatol 1989; 4:383-90. [AN 89278807]
28. Wisner JR Jr, Renner IG, Grendell JH, Niederau C, Ferrell LD. Gabexate mesilate protects against ceruleide-induced acute pancreatitis in the rats. Pancreas 1987; 2:181-6. [AN 87317533]
29. Lankisch PG, Pohl U, Goke B, Otto J, Wereszczynska-Siemiatkowska U, Grone HJ, Rahlf Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models. Gastroenterology 1989; 96:193-9. [AN 89078884]
30. Leonhardt U, Seidensticker F, Fussek M, Stockmann F, Creutzfeldt W. Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on thaurocholate induced pancreatitis. Gut 1990; 31:934-7. [AN 90353809]
31. Wakayama T, Itoh T, Shibayama K, Idezuki Y. Prevention of spread of experimental acute pancreatitis by intraductal administration of a synthetic protease inhibitor in dogs. Am J Gastroenterol 1989; 84:272-8. [AN 89148168]
32. Lankisch PG, Pohl U, Otto J. Synthetic versus natural protease inhibitors in acute experimental pancreatitis. Dig Dis Sci 1988; 33:1497-8. [AN 89030161]
33. Satake K, Koh I, Nishiwaki H, Umeyama. Toxic products in hemorragic ascitic fluid generated during experimental pancreatitis in dogs and a treatment which reduces their effect. Digestion 1985; 32:99-105. [AN 86005968]
34. Takasugi S, Yonezawa H, Ikei N, Kanno T. Prevention of acute experimental pancreatitis in rats and dogs by intraduodenal infusion of a synthetic trypsin inhibitor. Digestion 1982; 24:36-41. [AN 83028217]
35. Ono H, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Sakai Y, et al. Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat. Dig Dis Sci 1990; 35:787-92. [AN 90263566]
36. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, and C1 esterase. Biochim Biophys Acta 1977; 484:417-22. [AN 78021012]
37. Murakami K, Okajima K, Uchiba M, Okabe H, Takatsuki K. Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit Care Med 1996; 24:1047-53. [AN 96283687]
38. Aosasa S, Ono S, Seki S, Takayama E, Tadakuma T, Hiraide H, Mochizuki H. Inhibitory effect of protease inhibitor on endothelial cell activation. J Surg Res 1998; 80:182-7. [AN 99097387]
39. Jung SE, Yun IJ, Youn YK, Lee JE, Ha J, Noh DY, Kim SJ, Oh SK, Choe KJ. Effect of protease inhibitor on ischemia-reperfusion injury to rat liver. World J Surg 1999; 23:1027-31. [AN 99444176]
40. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001; 15:101-5. [AN 21115153]
41. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001; 69:241-7. [AN 21089199]
42. Iwadou H, Morimoto Y, Iwagaki H, Sinoura S, Chouda Y, Kodama M, et al. Differential cytokine response in host defence mechanisms triggered by gram-negative and gram-positive bacteria, and the roles of gabexate mesilate, a synthetic protease inhibitor. J Int Med Res 2002; 30:99-108. [AN 22020099]
43. Colasanti M, Persichini T, Venturini G, Menegatti E, Lauro GM, Ascenzi P. Effect of gabexate mesylate (FOY), a drug for serine proteinase-mediated diseases, on the nitric oxide pathway. Biochem Biophys Res Commun 1998; 246:453-6. [AN 98273302]
44. Harada H, Miyake H, Ochi K, Tanaka J, Kimura I. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 1991; 9:75-9. [AN 92078660]
45. Goebell H, and the German Pancreatitis Study Group. Multicenter double-blind study of gabexate-mesilate (FOY), given intravenously in low dose in acute pancreatitis. Digestion 1988; 40(Abstract):83.
46. Valderrama R, Perez-Mateo M, Navarro S, Vazquez N, Sanjose L, Adrian MJ, et al. Multicentre double blind trial of gabexate mesilate (FOY) in unselected patients with acute pancreatitis. Digestion 1992; 51:65-70. [AN 92363079]
47. Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993; 104:1165-70. [AN 93216029]
48. Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A): a prospective, randomized, double-blind multicenter study. Int J Pancreatol 1993;14:117-24. [AN 94110667]
49. Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000; 47:1147-50. [AN 20475104]
50. Messori A, Rampazzo R, Scroccaro G, Olivato R, Bassi C, Falconi M, et al. Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. Dig Dis Sci 1995; 40:734-8. [AN 95236882]
51. Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 1998; 12:237-45. [AN 98230183]
52. Bassi C, Falconi M, Caldiron E, Salvia R, Sartori N, Butturini G, Contro C, Marcucci S, Casetti L, Pederzoli P. Assessment and treatment of severe pancreatitis. Protease inhibitor. Digestion 1999; 60 (Suppl 1):5-8. [AN 99152090]
53. Uomo G, Pezzilli R, Cavallini G. Management of acute pancreatitis in clinical practice. ProInf-A.I.S.P Study Group. Progetto Informatizzato Pancreatite Acuta-Associazione Italiana Studio Pancreas. Ital J Gastroenterol Hepatol 1999; 31:635-42. [AN 20071775]
54. Mayumi T, Ura H, Arata S, Kitamura N, Kiriyama I, Shibuya K, et al. Evidence-based clinical practice guidelines for acute pancreatitis: proposals. J Hepatobiliary Pancreat Surg 2002; 9:413-22. [AN 22371302]
55. Di Francesco V, Mariani A, Angelini G, Masci E, Frulloni L, Talamini G, et al. Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. Dig Dis Sci 2002; 47:741-5. [AN 21987023]
56. Matsumura T, Yada S, Miyoshi Y, Komi N. Effect of synthetic protease inhibitor on the sphincter of Oddi function in dogs. Nippon Shokakibyo Gakkai Zasshi, 1991; 88: 2663-70. [AN 92099454]
57. Gottlieb K, Sherman S, Pezzi J, Esber E, Lehman GA. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastroenterol 1996; 91:1553-7. [AN 96322170]
58. Doppl WE, Weber HP, Temme H, Klor HU, Federlin K. Evaluation of ERCP- and endoscopic sphincterotomy-induced pancreatic damage: a prospective study on the time course and the significance of serum levels of pancreatic secretory enzymes. Eur J Med Res 1996; 1:303-11. [AN 98035917]
59. Petersson U, Borgstrom A, Ohlsson K, Fork FT, Toth E. Enzyme leakage, trypsinogen activation, and inflammatory response in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Pancreas 2002; 24:321-8. [AN 21959515]
60. Testoni PA, Bagnolo F, Caporuscio S, Lella F. Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis. Am J Gastroenterol 1999; 94:1235-41. [AN 99249279]
61. Testoni PA, Bagnolo F. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. Gastrointest Endosc 2001; 53:33-9. [AN 21067928]
62. Messman H, Vogt W, Holstege A, Lock G, Heinisch A, von Fürstenberg A, et al. Post-ERCP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997; 40:80-5. [AN 97300559]
63. Messmann H, Vogt W, Falk W, Vogl D, Zirngibl H, Leser HG, Scholmerich J. Interleukins and their antagonists but not TNF and its receptors are released in post-ERP pancreatitis. Eur J Gastroenterol Hepatol 1998; 10:611-7. [AN 99070730]
64. Kaw M, Singh S. Serum lipase, C-reactive protein, and interleukin-6 levels in ERCP-induced pancreatitis. Gastrointest Endosc 2001; 54:435-40. [AN 21460529]
65. Kuno N, Kasugai T, Oguri T, et al. Study on prevention of complications associated with endoscopic retrograde cholangiopancreatography (ERCP): a controlled trial of a new protease inhibitor, Foy, in hyperamylasemia following endoscopic retrograde cholangiopancreatography. Gendai Iryo 1978; 10:571.
66. Inada Y, Yamada M, Kadohara M, et al. The clinical study on the effect of Foy on complications following endoscopic retrograde cholangiopancreatography. Gendai Iryo 1980; 12:1493.
67. Tsunashima T, Kawai K, Suwaki K, et al. Experience with Foy for the prevention of acute pancreatitis after ERCP. Gendai Iryo 1979; 11:543.
68. Matsunaga E, Sato J, Nakashima H, et al. Effect of Foy on prevention of the occurrence of pancreatitis after ERCP. Gendai Iryo 1979; 11:1213.
69. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy - Italian Group. N Engl J Med 1996; 335:919-23. [AN 96365276]
70. Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003 in press.
71. Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56:488-95. [AN 22233811]
72. Eandi M., Rava A., Dirindin N., Vanara F. et al. Incremental cost-efficay analysis on the use of Gabexate mesylate for the prevention of pancreatitis related to endoscopic manipulation of the papilla of Vater: GRIGED study. Farmacoeconomia 1995; 12(Suppl.1):20-9.
73. Pasha TM, Therneau T, Petersen BT. Economic analysis of gabexate mesilate in post-ERCP pancreatitis. Gastroenterology 1997; 112:A471.